Abstract
This study summarizes major work which investigated the roles of glucagon like peptide-1 (GLP-1) and its receptor (GLP-1R); the use of GLP-1-R agonists and dipeptidyl peptidase 4 inhibitor in the management of type 2 diabetes mellitus. It focuses on the recent therapeutic development which has occurred in this field, and also discusses the potential treatments which can be discovered and implemented in the near future to design an effective therapy for type 2 diabetes mellitus.
| Original language | British English |
|---|---|
| Pages (from-to) | 225-230 |
| Number of pages | 6 |
| Journal | Diabetes and Metabolic Syndrome: Clinical Research and Reviews |
| Volume | 11 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 2017 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Dipeptidyl peptidase inhibitors
- Glucagon like peptide-1
- Type 2 diabetes mellitus
Fingerprint
Dive into the research topics of 'Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver